ArticlePloS one2010
A universal approach to eliminate antigenic properties of alpha-gliadin peptides in celiac disease.
Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 77 citations in OpenAlex.
- Evaluation of alpha-gliadin celiac disease epitopes in some Aegilops species containing the D genome.BMC plant biology · 2026Article
- Variations in the composition and frequency of celiac disease epitopes among synthetic wheat lines.Frontiers in plant science · 2024Article
- Characterizations of a neutralizing antibody broadly reactive to multiple gluten peptide:HLA-DQ2.5 complexes in the context of celiac disease.Nature communications · 2023Article
- Challenges facing sustainable protein production: Opportunities for cereals.Plant communications · 2023Review
- Unraveling the celiac disease-related immunogenic complexes in a set of wheat and tritordeum genotypes: implications for low-gluten precision breeding in cereal crops.Frontiers in plant science · 2023Article
- Exploring the alpha-gliadin locus: the 33-mer peptide with six overlapping coeliac disease epitopes in Triticum aestivum is derived from a subgroup of Aegilops tauschii.The Plant journal : for cell and molecular biology · 2021Article
- CRISPR/Cas9 Gene Editing of Gluten in Wheat to Reduce Gluten Content and Exposure-Reviewing Methods to Screen for Coeliac Safety.Frontiers in nutrition · 2020Review
- Pathogenesis of Celiac Disease and Other Gluten Related Disorders in Wheat and Strategies for Mitigating Them.Frontiers in nutrition · 2020Review
- Outlook for coeliac disease patients: towards bread wheat with hypoimmunogenic gluten by gene editing of α- and γ-gliadin gene families.BMC plant biology · 2019Article
- Proteinaceous Residue Removal from Oat β-Glucan Extracts Obtained by Alkaline Water Extraction.Molecules (Basel, Switzerland) · 2019Article
- Genetic and environmental factors affecting the expression of α-gliadin canonical epitopes involved in celiac disease in a wide collection of spelt (Triticum aestivum ssp. spelta) cultivars and landraces.BMC plant biology · 2018Article
- Development of Wheat With Hypoimmunogenic Gluten Obstructed by the Gene Editing Policy in Europe.Frontiers in plant science · 2018Article
- Production and molecular characterization of bread wheat lines with reduced amount of α-type gliadins.BMC plant biology · 2017Article
- Celiac disease: understanding the gluten-free diet.European journal of nutrition · 2017Review
- Development of TaqMan probes targeting the four major celiac disease epitopes found in α-gliadin sequences of spelt (Plant methods · 2017Article
- Why Oats Are Safe and Healthy for Celiac Disease Patients.Medical sciences (Basel, Switzerland) · 2016Review
- Molecular diversity of α-gliadin expressed genes in genetically contrasted spelt (Molecular breeding : new strategies in plant improvement · 2016Article
- Improving wheat to remove coeliac epitopes but retain functionality.Journal of cereal science · 2016Article
- 5-methylcytosine recognition by Arabidopsis thaliana DNA glycosylases DEMETER and DML3.Biochemistry · 2014Article
- Quantitative and qualitative differences in celiac disease epitopes among durum wheat varieties identified through deep RNA-amplicon sequencing.BMC genomics · 2013Article
Corrections and comments
- Erratum issuedMonserrat, Veronica [corrected to Montserrat, Veronica]
Authors and funding
14 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Celiac disease is caused by an uncontrolled immune response to gluten, a heterogeneous mixture of wheat storage proteins, including the α-gliadins. It has been shown that α-gliadins harbor several major epitopes involved in the disease pathogenesis. A major step towards elimination of gluten toxicity for celiac disease patients would thus be the elimination of such epitopes from α-gliadins. We have analyzed over 3,000 expressed α-gliadin sequences from 11 bread wheat cultivars to determine whether they encode for peptides potentially involved in celiac disease. All identified epitope variants were synthesized as peptides and tested for binding to the disease-associated HLA-DQ2 and HLA-DQ8 molecules and for recognition by patient-derived α-gliadin specific T cell clones. Several specific naturally occurring amino acid substitutions were identified for each of the α-gliadin derived peptides involved in celiac disease that eliminate the antigenic properties of the epitope variants. Finally, we provide proof of principle at the peptide level that through the systematic introduction of such naturally occurring variations α-gliadins genes can be generated that no longer encode antigenic peptides. This forms a crucial step in the development of strategies to modify gluten genes in wheat so that it becomes safe for celiac disease patients. It also provides the information to design and introduce safe gluten genes in other cereals, which would exhibit improved quality while remaining safe for consumption by celiac disease patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.